Clinical Efficacy of Salvianolate for Injection Combined with the Conventional Therapy in Ischemic Stroke / 中国药师

ABSTRACT

Objective:To investigate the clinical efficacy of salvianolate in the treatment of ischemic stroke(IS) and its effect on the serum levels of uric acid, hypoxia Inducible Factor-1α (HIF-1α), neuroglobin (NGB), hypersensitive C-reaction protein (hs-CRP),regulatory T cell(Treg) and helper T lymphocyte 17 (Th17). Methods:Totally 196 IS patients in our hospital were analyzed and divided into the control group(n=96) and the observation group(n=96). The patients in the control group were treated with the traditional therapy,and the patients in the observation group were treated with salvianolate additionally. The clinical effect and disabili-ty were observed;and the serum levels of uric acid,HIF-1α,NGB,hs-CRP,Treg and Th17 were compared between the groups. Re-sultsBefore the treatment,there were no differences in uric acid,HIF-1α,NGB,hs-CRP,Treg and Th17 between the groups(P>0.05). After the 14-day treatment,the effective rate was 69.79% in the observation group,which was higher than that in the control group (P<0.05). NIHSS scores and mRS scores of the two groups were lower than baseline values (55.21%,P<0.05). After 3-month follow-up,NIHSS scores,mRS scores and the disability rate(12.5%) in the observation group were obviously lower than those in the control group(P<0.05). After the 14-day treatment,the serum levels of uric acid,HIF-1α,NGB,and hs-CRP in the obser-vation group were lower than those in the control groups (P<0.05). Besides, the patients in the observation group were with more Treg and fewer Th17 than the control group and baseline value (P<0.05). Conclusion:The application of salvianolate in the treat-ment of ischemic stroke can effectively improve the disability and neurological function defects,which should be recommended for the clinical use as an effective drug.